<DOC>
	<DOCNO>NCT01751555</DOCNO>
	<brief_summary>This Phase 4 single-arm , post-marketing clinical trial evaluate efficacy safety tenofovir disoproxil fumarate , lamivudine efavirenz adult human immunodeficiency virus-1 hepatitis B virus coinfection .</brief_summary>
	<brief_title>Efficacy Safety TDF+3TC+EFV Adults With HIV/HBV Coinfection</brief_title>
	<detailed_description>HIV/HBV co-infections frequently observe due share route transmission . TDF 3TC nucleotide analogue inhibit HIV HBV DNA polymerases . There high risk cause drug resistance treat HBV HIV infection 3TC TDF monotherapy combination trerapy . Combination tharapy could decrease drug resistance . China 's HIV epidemic remain one low prevalence overall , pocket high infection among specific sub-populations locality . China high endemicity hepatitis B . A substantial proportion HIV-infected individual co-infected HBV . TDF + 3TC + EFV common regimen HIV/HBV co-infected Chinese individual . The purpose study study determine whether TDF safe patient HIV HBV co-infection combination TDF+3TC+EFV suppress HIV HBV viral load LDL week 48 treatment patient HIV HBV co-infeciton.This study enroll 100 adult subject follow patient 48 weekes.There one enrollment visit ( baseline ) visit 2,4,8,12,24,36,48 week initiation study regimen .</detailed_description>
	<mesh_term>Coinfection</mesh_term>
	<criteria>Serologicallyconfirmed HIV HBV infection Willingness participate clinical trial No previous current use antiretroviral regimen Clinical condition stable Blood creatinine less 3 time upper limit normal value . HBV DNA &gt; 1000copies/ml , Tbil &lt; 34umol/L , ALT &lt; 400U/L With clinical indication HAART Patient refuse sign consent participate Unwillingness adhere visit schedule maintain adherence medication Illnesses serve likely require hospitalization With condition suitable enrol subject medical review</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HBV co-infection ART TDF</keyword>
</DOC>